GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Betta Pharmaceuticals Co Ltd (SZSE:300558) » Definitions » EV-to-EBITDA

Betta Pharmaceuticals Co (SZSE:300558) EV-to-EBITDA : 40.59 (As of Jun. 06, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Betta Pharmaceuticals Co EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Betta Pharmaceuticals Co's enterprise value is ¥17,868 Mil. Betta Pharmaceuticals Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was ¥440 Mil. Therefore, Betta Pharmaceuticals Co's EV-to-EBITDA for today is 40.59.

The historical rank and industry rank for Betta Pharmaceuticals Co's EV-to-EBITDA or its related term are showing as below:

SZSE:300558' s EV-to-EBITDA Range Over the Past 10 Years
Min: 29.35   Med: 69.42   Max: 176.92
Current: 40.59

During the past 13 years, the highest EV-to-EBITDA of Betta Pharmaceuticals Co was 176.92. The lowest was 29.35. And the median was 69.42.

SZSE:300558's EV-to-EBITDA is ranked worse than
87.25% of 714 companies
in the Drug Manufacturers industry
Industry Median: 14.065 vs SZSE:300558: 40.59

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-06), Betta Pharmaceuticals Co's stock price is ¥37.18. Betta Pharmaceuticals Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥0.930. Therefore, Betta Pharmaceuticals Co's PE Ratio for today is 39.98.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Betta Pharmaceuticals Co EV-to-EBITDA Historical Data

The historical data trend for Betta Pharmaceuticals Co's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Betta Pharmaceuticals Co EV-to-EBITDA Chart

Betta Pharmaceuticals Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 57.90 49.94 55.68 40.42 34.31

Betta Pharmaceuticals Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 109.33 58.84 51.31 34.31 43.49

Competitive Comparison of Betta Pharmaceuticals Co's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Betta Pharmaceuticals Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Betta Pharmaceuticals Co's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Betta Pharmaceuticals Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Betta Pharmaceuticals Co's EV-to-EBITDA falls into.



Betta Pharmaceuticals Co EV-to-EBITDA Calculation

Betta Pharmaceuticals Co's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=17868.378/440.247
=40.59

Betta Pharmaceuticals Co's current Enterprise Value is ¥17,868 Mil.
Betta Pharmaceuticals Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥440 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Betta Pharmaceuticals Co  (SZSE:300558) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Betta Pharmaceuticals Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=37.18/0.930
=39.98

Betta Pharmaceuticals Co's share price for today is ¥37.18.
Betta Pharmaceuticals Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.930.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Betta Pharmaceuticals Co EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Betta Pharmaceuticals Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Betta Pharmaceuticals Co (SZSE:300558) Business Description

Traded in Other Exchanges
N/A
Address
No.355, Xingzhong Road, Yuhang Economic and Technological Development Zone, Zhejiang Province, Hangzhou, CHN
Betta Pharmaceuticals Co Ltd is a hi-tech pharmaceutical enterprise focuses on research and development of innovative medicines. The company's drug is used for various diseases such as malignant tumors, diabetes, and cardio-cerebrovascular disease. Further, it offers Icotinib hydrochloride, an orally administered small-molecule and a reversible tyrosine kinase inhibitor, which is used for the treatment of non-small-cell lung cancer. Geographically, the group operates through China.
Executives
Wang Jia Bing Directors, executives
Ding Lie Ming Directors, executives
Cai Wan Yu Executives

Betta Pharmaceuticals Co (SZSE:300558) Headlines

No Headlines